Status:
NOT_YET_RECRUITING
A Phase Ib Study of QLS4131 in Subjects With Systemic Lupus Erythematosus
Lead Sponsor:
Qilu Pharmaceutical Co., Ltd.
Conditions:
Systemic Lupus Erythematosus
Eligibility:
All Genders
18-70 years
Phase:
PHASE1
Brief Summary
The goal of this open label, dose escalation phase 1b clinical trial is to investigate the safety, tolerability, pharmacokinetic, pharmacodynamics, immunogenicity and preliminary clinical efficacy of ...
Eligibility Criteria
Inclusion
- Aged 18 to 70 (inclusive);
- Diagnosis of SLE according to the 2019 European League Against Rheumatism/American College of Rheumatology (ACR) Classification Criteria at least 12 weeks or more prior to screening;
- Participants with positive antinuclear antibody (ANA) (≥ 1:80), or positive anti-dsDNA antibody and/or positive anti-Sm antibody at screening;
- Active SLE disease at screening, as demonstrated by a SLEDAI-2K \>= 8 at screening, or SLEDAI-2K \>= 6 at the presence of low complement and/or positive anti-dsDNA antibodies;
- Current receipt of one or more of the following classes of standard therapies for the treatment of SLE at stable doses: oral corticosteroids, antimalarial agents, and conventional immunosuppressants:
- For participants receiving an oral corticosteroid, treatment with ≤40 mg/day prednisone or equivalent, at a dose that has been stable for at least 4 weeks prior to first dose;
- For participants receiving an antimalarial, the medication(s) must have been at a stable dose ≥ 4 weeks prior to the first dose;
- For participants receiving immunosuppressants, treatment with a single immunosuppressant at a stable dose for ≥ 4 weeks prior to the first dose: conventional immunosuppressants include azathioprine, mycophenolate mofetil, mycophenolic acid, and methotrexate (oral, subcutaneous or intravenous routes).
- Participants who understand and abide by the study procedures, voluntarily participate in this study, and sign the Informed Consent Form in person.
Exclusion
- Participants with known intolerance or allergy to the investigational product or drugs that may be used in the study (e.g., Tocilizumab) and any components;
- Participants with active severe active or unstable lupus-associated neuropsychiatric disease;
- Participants with other autoimmune diseases that may affect the efficacy evaluation;
- Participants with poorly controlled hypertension and diabetes;
- Participants with severe lupus nephritis;
- Participants with a history of malignancy within 5 years prior to screening;
- Participants with a previous history of vital organ transplantation;
- Participants who have had opportunistic infections within 12 weeks prior to the first dose;
- Receipt of any CAR-T, CAR-NK or other gene therapy;
- Pregnant or lactating women.
Key Trial Info
Start Date :
June 1 2025
Trial Type :
INTERVENTIONAL
Allocation :
ESTIMATED
End Date :
December 1 2026
Estimated Enrollment :
108 Patients enrolled
Trial Details
Trial ID
NCT07001839
Start Date
June 1 2025
End Date
December 1 2026
Last Update
June 3 2025
Active Locations (0)
Enter a location and click search to find clinical trials sorted by distance.
No Results Found
We couldn’t find results for the location/zipcode entered or within the selected range. Please check your input or adjust your search.